As the use of neoadjuvant chemotherapy is gradually increased in the treatment of breast cancer, evaluating its therapeutic effect is gaining importance. However, tumors are markedly heterogeneous in cells, micro-environmental factors and vasculature structures, which manifests as radiologic heterogeneity. A few studies have been trying to extract heterogeneity metrics from regions of interest (ROIs) such as by means of histogram analysis. Thus, the aim of our study is to investigate the feasibility of whole-lesion histogram analysis of pharmacokinetic parameters in breast T1-weighted dynamic contrast-enhanced MR imaging (DCE-MRI) for differentiating the malignant from benign breast lesions.
This abstract and the presentation materials are available to members only; a login is required.